Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTK650)

• Drug Name: 1,2,3,4,6-penta-O-galloyl-beta-D-glucose Drug Info
• Synonyms: Pentagalloyl glucose; Penta-O-galloyl-beta-glucoside

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 65238
  ChEBI ID: CHEBI:18082
  CAS Number: CAS 14937-32-7
  TTD Drug ID: DMTK650
  VARIDT Drug ID: DR01470

Molecule-Related Drug Atlas

Drug(s) Targeting Xanthine dehydrogenase/oxidase (XDH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Allopurinol	DMLPAOB	Gout	FA25	Approved	[5]
Febuxostat	DMDEXQ0	Hyperuricaemia	5C55.Y	Approved	[6]
Fosdenopterin	DMR0TYK	Molybdenum cofactor deficiency	5B5K.A	Approved	[7]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
Oxypurinol	DMURH4X	Heart failure	BD10-BD13	Phase 2/3	[9]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[10]
Topiroxostat	DMA04DE	Gout	FA25	Phase 2	[11]
TMX-049	DME8PFQ	Diabetic nephropathy	GB61.Z	Phase 2	[12]
LC-350189	DMHT3CB	Gout	FA25	Phase 1	[13]
Azaindole derivative 5	DMD2BL3	N. A.	N. A.	Patented	[14]

Drug(s) Targeting Coagulation factor Xa (F10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apixaban	DM89JLN	Thrombosis	DB61-GB90	Approved	[15]
Rivaroxaban	DMQMBZ1	Deep vein thrombosis	BD71	Approved	[16]
DU-176b	DMCIJBH	Atrial fibrillation	BC81.3	Approved	[17]
Emicizumab	DM0AQ83	Factor VIII deficiency	3B10	Approved	[18]
BETRIXABAN	DM2C4RF	Venous thromboembolism	BD72	Approved	[19]
Lmw heparin	DMJPD06	Coagulation defect	3B10.0	Approved	[20]
Nadroparin calcium	DMBNKST	Coagulation defect	3B10.0	Approved	[21]
Fondaparinux sodium	DMWS3FH	Deep vein thrombosis	BD71	Approved	[22]
Danaparoid	DM6CLBN	Deep venous clot	BD71	Approved	[23]
Coagulation Factor IX	DM8HBJI	Haemophilia B	3B11.0	Approved	[24]

Drug(s) Targeting Squalene monooxygenase (SQLE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Naftifine	DMHVBG1	Dermatomycosis	EA60	Approved	[25]
Tolnaftate	DM28MU7	Dermatophytosis	1F28.2	Approved	[26]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[2]
FR-194738	DMNACIV	Hypercholesterolaemia	5C80.0	Terminated	[27]
SDZ-87-469	DMBY6CQ	Coronary artery disease	BA80	Terminated	[26]
NB-598	DMJVTQN	N. A.	N. A.	Terminated	[28]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[2]
Pedunculagin	DMKLRCX	Discovery agent	N.A.	Investigative	[2]
CORILAGIN	DMAC698	Discovery agent	N.A.	Investigative	[2]
ETHYLGALLATE	DMJ6PB8	Discovery agent	N.A.	Investigative	[2]

Drug(s) Targeting Coagulation factor IIa (F2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Argatroban	DMFI46A	Thrombosis	DB61-GB90	Approved	[29]
Pyridoxal Phosphate	DMO2K0J	Malnutrition	5B50-5B71	Approved	[30]
Bivalirudin	DMECRX1	Thrombocytopenia	3B64	Approved	[31]
Ximelegatran	DMU8ANS	Myocardial infarction	BA41-BA43	Approved	[32]
Dabigatran	DMDI6R4	Stroke	8B20	Approved	[33]
Desirudin Recombinant	DM2BTFN	Coagulation defect	3B10.0	Approved	[34]
Human prothrombin complex concentrate	DMPHVQ1	Bleeding disorder	GA20-GA21	Approved	[35]
Lepirudin	DM1I3D5	Thrombocytopenia	3B64	Approved	[36]
Anisindione	DM2C48U	Coagulation defect	3B10.0	Approved	[37]
ATryn antithrombin	DM79Y2T	Multiple sclerosis	8A40	Approved	[38]

Drug(s) Affected By DNA oxidative demethylase ALKBH2 (ALKBH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[39]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[40]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[40]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[41]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[42]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[43]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[44]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[45]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[46]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[47]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Coagulation factor IIa (F2)	TT6L509	THRB_HUMAN	Inhibitor	[1]
Coagulation factor Xa (F10)	TTCIHJA	FA10_HUMAN	Inhibitor	[1]
Squalene monooxygenase (SQLE)	TTE14XG	ERG1_HUMAN	Inhibitor	[2]
Xanthine dehydrogenase/oxidase (XDH)	TT7RJY8	XDH_HUMAN	Inhibitor	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
DNA oxidative demethylase ALKBH2 (ALKBH2)	OTSQW0BG	ALKB2_HUMAN	Gene/Protein Processing	[4]

References

• [1] Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60.
• [2] Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
• [3] Pentagalloylglucose, a xanthine oxidase inhibitor from a Paraguayan crude drug, "Molle-i" (Schinus terebinthifolius). J Nat Prod. 1989 Jan-Feb;52(1):210-1.
• [4] Hydrolyzable Tannins Are Iron Chelators That Inhibit DNA Repair Enzyme ALKBH2. Chem Res Toxicol. 2019 Jun 17;32(6):1082-1086. doi: 10.1021/acs.chemrestox.8b00398. Epub 2019 May 28.
• [5] Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1.
• [6] Clinical pipeline report, company report or official report of Takeda (2009).
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [8] Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009 Apr;72(4):725-31.
• [9] Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol. 1988 Jan 15;37(2):349-52.
• [10] Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
• [11] QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52.
• [12] Clinical pipeline report, company report or official report of Teijin Pharma.
• [13] Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49.
• [14] An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
• [15] Pfizer. Product Development Pipeline. March 31 2009.
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359).
• [18] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [19] Company report (Portola)
• [20] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [21] Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81.
• [22] Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24.
• [23] Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6.
• [24] Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24.
• [25] Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother. 1996 Feb;40(2):443-7.
• [26] Effects of squalene epoxidase inhibitors on Candida albicans. Antimicrob Agents Chemother. 1992 Aug;36(8):1779-81.
• [27] Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738. Bioorg Med Chem Lett. 2004 Feb 9;14(3):633-7.
• [28] Squalene epoxidase as hypocholesterolemic drug target revisited. Prog Lipid Res. 2003 Jan;42(1):37-50.
• [29] Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44.
• [30] New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32.
• [31] New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8.
• [32] Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
• [33] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [34] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [35] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
• [36] Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl. 1999 Nov;(72):S46-50.
• [37] Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6.
• [38] Antithrombin III Utilization in a Large Teaching Hospital. P T. 2013 December; 38(12): 764-767, 779.
• [39] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [40] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [41] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [42] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [43] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [44] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [45] Down-regulation of ALKBH2 increases cisplatin sensitivity in H1299 lung cancer cells. Acta Pharmacol Sin. 2011 Mar;32(3):393-8. doi: 10.1038/aps.2010.216. Epub 2011 Jan 31.
• [46] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [47] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.